KB 707
Alternative Names: KB-707Latest Information Update: 10 Mar 2026
At a glance
- Originator Krystal Biotech
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Interleukin 12 replacements; Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Lung cancer; Non-small cell lung cancer
- Suspended Solid tumours
Most Recent Events
- 19 Feb 2026 KB 707 is covered by patent protection in USA and South Africa
- 09 Feb 2026 KB 707 receives Regenerative Medicine Advanced Therapy (RMAT) status for Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA
- 03 Nov 2025 Suspended - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Intratumoural)